-
Product Insights
NewLupus Nephritis – Drugs In Development, 2024
Empower your strategies with our Lupus Nephritis – Drugs In Development, 2024 report and make more profitable business decisions. Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects various organs, tissues, and systems within the body. Lupus nephritis specifically involves inflammation of the kidneys, leading to kidney damage and impaired kidney function. In systSLE, the body's immune system mistakenly attacks its own tissues and organs, including the kidneys, causing inflammation. Not all individuals with...
-
Product Insights
NewRetinal Degeneration – Drugs In Development, 2024
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis...
-
Product Insights
NewKidney Fibrosis – Drugs In Development, 2024
Empower your strategies with our Kidney Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors, and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea, and vomiting. The condition may be managed with...
-
Product Insights
NewPost Menopausal Osteoporosis – Drugs In Development, 2024
Empower your strategies with our Post Menopausal Osteoporosis – Drugs In Development, 2024 report and make more profitable business decisions. Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure, and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues. The Post Menopausal Osteoporosis drugs in development market research report...
-
Product Insights
NewSicca Syndrome (Sjogren) – Drugs In Development, 2024
Empower your strategies with our Sicca Syndrome (Sjogren) – Drugs In Development, 2024 report and make more profitable business decisions. Sjogren's syndrome is an autoimmune disease. It involves the inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling, and stiffness. Predisposing factors include age, sex, and rheumatic disease. The Sicca Syndrome (Sjogren) drugs in development market research report provide comprehensive...
-
Product Insights
NewBeta Thalassaemia – Drugs In Development, 2024
Empower your strategies with our Beta Thalassaemia – Drugs In Development, 2024 report and make more profitable business decisions. Beta-thalassemia is a genetic blood disorder characterized by reduced or absent production of beta-globin chains, a component of hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. This deficiency leads to anemia and various complications. Beta-thalassemia is classified based on the severity of symptoms: In beta-thalassemia major (Cooley's anemia), individuals have little or no beta-globin production, leading...
-
Product Insights
NewDementia Associated With Alzheimer’s Disease – Drugs In Development, 2024
Empower your strategies with our Dementia Associated With Alzheimer's Disease – Drugs In Development, 2024 report and make more profitable business decisions. Alzheimer's disease (AD) is the most common cause of dementia. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and changes in behavior and thinking skills that interfere with daily functioning. Early symptoms may include mild forgetfulness, difficulty recalling recent events or information, and trouble with problem-solving or complex tasks. One of the hallmark features of...
-
Product Insights
NewEpidermolysis Bullosa – Drugs In Development, 2024
Empower your strategies with our Epidermolysis Bullosa – Drugs In Development, 2024 report and make more profitable business decisions. Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin; deformity or loss of fingernails and toenails; internal blistering including on the throat, esophagus, upper airway, stomach, intestines, and urinary tract; skin thickening on palms and soles of the feet (hyperkeratosis); and scalp blistering, scarring, and hair loss...